The goal of this clinical trial is to learn if use of topical benzocaine prior to the injection of lidocaine is effective in decreasing pain experienced during IUD insertion in patients 18 or older. The main question it aims to answer is:
Does topical use of benzocaine prior to lidocaine injection during IUD insertion effectively decrease pain experienced?
Researchers will compare benzocaine/lidocaine to benzocaine/placebo, placebo/lidocaine, and placebo/placebo to see if use of benzocaine prior to lidocaine injection works more effectively to decrease pain experienced rather than lidocaine, benzocaine, or placebo use alone.
Participants will:
* Arrive to clinic for previously scheduled IUD insertion
* Be screened, approached by research staff, and consented to join the trial
* Complete a demographic questionnaire
* Be randomly and blindly assigned to one of four groups
* Placebo/Placebo
* Placebo/Lidocaine
* Benzocaine/Placebo
* Benzocaine/Lidocaine
* All groups will be given 600mg of ibuprofen prior to procedure
* Be asked to rate their pain on a visual scale of 1-10 during several distinct points of the procedure.
* Be sent an optional survey to their email after the procedure

Start Date01 May 2025

Sponsor / Collaborator

University of Missouri

NCT05917119

/ RecruitingNot ApplicableIIT

Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea

Persistent daytime symptoms of sleepiness in individuals with obstructive sleep apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. This study will explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP. BLT will be delivered via therapy glasses in a cross-over design, where each participant will be exposed to active treatment and sham treatment (4 weeks in each arm) in a randomized order. The hypothesis is that participants will demonstrate improvements in the variables of interest during the four-week active treatment portion of the eight-week crossover study, compared to the four-week sham treatment portion.

Start Date26 Oct 2024

Sponsor / Collaborator

VA Office of Research and Development

NCT06569537

/ RecruitingPhase 4IIT

Comparison of Compounded Topical Anesthetics for Pain Relief of Intense Pulsed Light, Pulse Dye Laser, and Microneedling Treatments

The primary objective for this pilot study is to evaluate the efficacy of the compounded topical anesthetic Benzocaine 20%/ Lidocaine 8%/Tetracaine 4% (BLT) compared to 4% Lidocaine topical in providing relief of pain during IPL, PDL, and microneedling procedures.

Start Date22 Oct 2024

Sponsor / Collaborator

Dartmouth-Hitchcock Medical Center

100 Clinical Results associated with Ethyl Aminobenzoate

100 Translational Medicine associated with Ethyl Aminobenzoate

100 Patents (Medical) associated with Ethyl Aminobenzoate

7,961

Literatures (Medical) associated with Ethyl Aminobenzoate

01 Aug 2025·TALANTA

Development of a regression equation to estimate a quantifiable basic compound by the reduction prepeak measurement of quinone derived from surplus acid

Article

Author: Yamamoto, Kazuhiro ; Kubo, Hinako ; Machida, Koichi ; Hakamata, Hideki ; Kotani, Akira

We have previously reported the electrochemical analysis that is coupled with the concept of acid-base back titration and the electrochemical sensing for acids based on the reduction of 3,5-di-tert-butyl-1,2-benzoquinone (DBBQ) for determining inorganic basic compounds and amino acids. The purpose of this study is to develop a regression equation to estimate quantifiable basic compounds by this electrochemical analysis. Through the analysis of 23 compounds with various basic and acidic groups, we found that there are some quantifiable and non-quantifiable basic compounds. For example, 4-aminophenol is quantifiable because the reduction prepeak current height of DBBQ derived from surplus HCl after neutralization with 4-aminophenol was linearly decreased with increasing 4-aminophenol concentration (r² = 0.988). In contrast, 4-aminobenzoic acid is non-quantifiable because the above voltammetric behaviors were not observed. From the relationships between the predicted pK_b and pK_a values of the quantifiable and non-quantifiable compounds, we found that a quantifiable basic compound without an acidic group satisfies pK_b < 12, and a quantifiable basic compound with an acidic group satisfies the following equation: pK_b < -0.0399(pK_a)² + 1.25pK_a + 2.12. These findings are useful to predict interfering substances in analyses of real samples with complicated matrixes and to estimate quantifiable basic compounds by this electrochemical analysis.

01 Jun 2025·JOURNAL OF MOLECULAR STRUCTURE

Self-assemblies of two ring salicylaldimine at low temperatures: Mesophase behaviour and DFT investigations

Author: Nakum, Kiran J. ; Bhatt, Ronak ; Geres, Marium ; Hagar, Mohamed ; Joshi, Vijay K. ; Wani, Tanveer ; Joshi, Richa ; Katariya, Kanu

In the area of liquid crystalline compounds, development of low temperature liquid crystals (LTLCs) remained stimulating.One of the significant challenges in the development of LTLCs is maintaining stability in the desired liquid crystalline phase while preventing crystallization at low temperaturesIn this context, the present manuscript describes the synthesis of a series of new LCs (n-alkyl 4-((4-decyloxy)-2 hydroxy benzylidene)amino)benzoates, bearing two rings linked by imine linkage.One aromatic ring carries decyloxy chain while the other carries ester moiety with systematically varied alkoxy chains.New mols. revealed enantiotropic smectic-A behavior below 117°C studied initially by POM and confirmed by DSC anal.Further, the VT-XRD showed the parallel mol. arrangement of SmA phase.Addnl., computational analyses using D. Functional Theory were conducted to investigate aspect ratio, dipole moment, mol. polarizability and their correlation with thermal stability.Mol. electrostatic potential mapping was applied to understand the influence of alkoxy chain length on distribution of charges and interactions between mols.Frontier MOs anal. provided insights into HOMO-LUMO energy levels, chem. hardness (η) and global softness (S).These combined exptl. and computational approaches will facilitate a deeper understanding of the structure-property relationships that govern the mesomorphic behavior of salicylaldimine liquid crystals, with a focus on optimizing mol. design for advanced liquid crystalline applications.

01 Jun 2025·CONTACT DERMATITIS

Prevalence and Determinants of Sensitisation to Neomycin in North‐Eastern Italy, 1997–2021

Article

Author: Cegolon, Luca ; Larese Filon, Francesca

ABSTRACT:

Background:

Allergic contact dermatitis (ACD) induced by topical application of neomycin is frequently reported.

Objectives:

This multi‐center study investigated prevalence and determinants of neomycin sensitisations in 30 629 outpatients from North‐eastern Italy during 1997–2021.

Patients and Methods:

European baseline and extended Triveneto series were applied on the upper back of patients patch testing for suspected ACD and removed after 48 h.

Results:

Prevalence of neomycin sensitisation was 2.29% (=701/30 629), significantly decreasing over time, especially after 2003. Neomycin sensitisation increased with age, especially in female patients older than 60 with leg dermatitis. The majority of patients sensitised to neomycin (74.5%) tested positive also against other haptens, particularly ingredients included in creams and emollients, as lanolin or benzocaine or preservatives as thimerosal or parabens.

Conclusions:

The decreasing prevalence of neomycin sensitisation over time likely reflected reduced accessibility and circulation of neomycin in Italy, due to containment of prescriptions and over‐the‐counter accessibility. Older individuals are typically more likely to be treated by topical medications and antibiotics as neomycin for various conditions, including stasis dermatitis. Since ACD caused by topical medications is relatively easy to miss, comprehensive drug history and patch testing are essential for any patient with suspected sensitisation caused by neomycin.

News (Medical) associated with Ethyl Aminobenzoate

10 Mar 2025

·www.pharmaceutical-technology.com

Alliance Pharma agrees to £362m acquisition by DBAY

DBAY advisors initially approached Alliance Pharma in 2024. Credit: DjelicS via Getty Images. UK-based Alliance Pharma has agreed to a final increased cash offer from asset management company DBAY Advisors, valuing the former at approximately £362m ($467.5m). The offer, made through a newly formed company called Aegres Bidco Limited, will see DBAY acquire all shares in Alliance, except those it already owns through its affiliates, for 64.75p per share. This represents a 3.6% increase from DBAY’s initial offer of 62.5p per share in January 2025 and a 46% premium on Alliance’s share price as of 9 January 2025, the day before the offer period began. Alliance Pharma specialises in the marketing and distribution of consumer healthcare products and prescription medicines. Its portfolio includes Kelo-Cote, a scar treatment; and Anbesol (benzocaine), an oral pain relief product. DBAY initially approached Alliance last year, following a series of challenges faced by the company, including the delayed publication of its annual results and the resignation of its CEO Peter Butterfield. Having gradually increased its stake in the company over two years, DBAY now holds a 27.9% share of Alliance. In its initial takeover offer, DBAY stated that it believed Alliance had “strong future prospects” but required significant operational changes and increased investment to maximise its growth potential. The asset management company argued that such changes would be more effectively implemented away from the pressures of the public market. In January 2025, Alliance’s board of directors recommended shareholders accept the initial offer of 62.5p per share. However, after receiving feedback from shareholders, the scheduled general meeting last month was adjourned to allow for further discussions. According to a 10 March filing on the London Stock Exchange, DBAY will fund the acquisition through a combination of equity investments from its affiliated funds and external financing, with a small portion of shares in Midco, the parent company of Bidco, being offered to certain lenders. Shareholders are expected to vote on the proposal at a rescheduled meeting on 13 March 2025. If approved, the deal is anticipated to be completed in the first half of 2025, resulting in Alliance Pharma becoming a privately owned company under DBAY’s control. In September 2024, Alliance reported underlying revenue of £84m for the six months to 30 June 2024, reflecting an increase from £81.4m in the same period the previous year. Profit before tax also rose year-on-year, reaching £12.7m compared to £10.3m in 2023.

AcquisitionFinancial StatementExecutive Change

22 Dec 2023

·www.biospace.com

Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene

TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a recent review by our manufacturer and their third-party lab found that a sample from one lot of the product showed a low level of benzene came from the propellant that sprays the product out of the can. Importantly, no other lots of Americaine® 20% Benzocaine Topical Anesthetic Spray (either before or after this batch code) are in the scope of this recall and may continue to be used by consumers safely and as intended. Risk Statement: Benzene is classified as a human carcinogen. Exposure to benzene can occur by inhalation, orally, and through the skin and it potentially can result in cancers including leukemia and blood cancer of the bone marrow and blood disorders which can be life threatening. Insight is recalling these products out of an abundance of caution. To date, the Company has not received any serious adverse events related to this recall. Benzene is ubiquitous in the environment. Humans around the world have daily exposures to it indoors and outdoors from multiple sources. Americaine® 20% Benzocaine Topical Anesthetic Spray is packaged in white aerosol cans with Teal caps with Lot codes located on the bottom of the can. Samples of the recalled lot below have been found to contain trace levels of Benzene related to the propellant that sprays the product out of the can. Benzene is not an ingredient in any Americaine products. Product NDC Lot Code Expiration Package Size Americaine® 20% Benzocaine Topical Anesthetic Spray 63736-378-02 1A16420 01/25 2 oz / 57 g The affected Americaine® 20% Benzocaine Topical Anesthetic Spray lot was distributed nationwide in the United States through a limited number of retailers and online. Insight has notified retailers via overnight mail to remove any remaining recalled product from shelves and follow the instructions provided in the Drug Recall Notification. The company will also offer reimbursement for consumers who have purchased Americaine® 20% Benzocaine Topical Anesthetic Spray marked with the lot code in the table above. Consumers can contact Insight Pharmaceuticals via e-mail at medicalaffairs@prestigebrands.com, through its website at , or by phone at (800) 344-7239 on Monday – Friday 8:30-5:30 eastern time to receive a full refund by providing a picture of the bottom of the can of the Americaine® 20% Benzocaine Topical Anesthetic Spray with the affected lot number. Consumers that have product which is being recalled should stop using the product immediately and appropriately discard after taking the picture. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this anesthetic product. No serious adverse events have been reported to date. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. A photo accompanying this announcement is available at . Investor Relations Contact Phil Terpolilli, CFA, 914-524-6819 irinquiries@prestigebrands.com Americaine® 20% Benzocaine Topical Anesthetic Spray Americaine® 20% Benzocaine Topical Anesthetic Spray

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

100 Deals associated with Ethyl Aminobenzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D00552	Ethyl Aminobenzoate	D04AB04 R02AD01 N01BA05	DB01086

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	Japan	Agsa Japan Co., Ltd.	11 May 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent aphthous ulcer	Phase 3	China	Shanghai Institute of Pharmaceutical Industry	13 Aug 2014
Acute otitis media	Phase 3	United States	Arbor Pharmaceuticals, Inc.	01 Dec 2013
Pain	Phase 3	United States	Arbor Pharmaceuticals, Inc.	01 Dec 2013
Earache	Phase 2	United States	Arbor Pharmaceuticals, Inc.	01 May 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group)	nxvlvuvrsp = hpfvphbuik zykgpbjjty (vtcysotjxz, itzwdtxsgd - outguxhznc) View more	-	16 May 2019
				Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support)	nxvlvuvrsp = chnkqahqqn zykgpbjjty (vtcysotjxz, kzfuwolggc - sdwjkkwewh) View more
NCT02379221 (CTgov)	Not Applicable	Anesthesia	49	Topical+epinephrine+benzocaine+lidocaine	wftoopstle(bqssfmtnwb) = irapceqwmc tiigitufvc (ulowbzdaru, thnzsblnua - mzwrtzmwnx) View more	-	24 Oct 2018
NCT02037893 (CTgov)	Phase 2	Acute otitis media \| Pain	112	Placebo Otic solution+Benzocaine otic solution+Antipyrine (Antipyrine and Benzocaine Otic Solution)	bmhbjtmesr(byuukaikzd) = lwxtyoexax vzjydvcstd (ltrgtlhspe, 3.43) View more	-	31 Aug 2018
				Placebo Otic solution+Antipyrine Otic Solution (Antipyrine Otic Solution)	bmhbjtmesr(byuukaikzd) = binpsusaxo vzjydvcstd (ltrgtlhspe, 2.82) View more
NCT01925469 (CTgov)	Phase 4	Analgesia	30	Benzocaine (Benzocaine)	cbxplbooyi(yemfsnirik) = wsjbzcumdl aelubpjxgz (gjgrcxweyr, gshkxvrhoc - hpmbqcpkao) View more	-	28 Apr 2017
				Saline spray (Saline Spray)	cbxplbooyi(yemfsnirik) = clvupggssw aelubpjxgz (gjgrcxweyr, sxefygkyea - wdfxbzmfsq) View more
NCT01925469 (Pubmed \| Reprod Biomed Online)	Phase 4	Pain, Postoperative	30	Benzocaine spray	fzdrrxqqjc(uocrlzhafq) = rooerdsjss gofintybfe (tfeknzvrhk, -7.4 to 98.8) View more	-	01 Jun 2014
				Saline spray	fzdrrxqqjc(uocrlzhafq) = qrcpqygtvx gofintybfe (tfeknzvrhk, 19.8 - 100) View more
NCT00474175 (CTgov)	Phase 4	Toothache	577	placebo+benzocaine (Placebo)	pnyfrmorgr = mxqbzzwixe vifckgijvw (tdkwvpnusj, reqtpgfoll - urlqldizes) View more	-	18 Jan 2012
				Benzocaine (Benzocaine 10%)	pnyfrmorgr = cofkomqiza vifckgijvw (tdkwvpnusj, crwcbaosls - jrpsazlcuv) View more
Pubmed \| J Am Dent Assoc	Not Applicable	-	-	Refrigerant	hrcrsqlvyp(jsaoohoooj) = qblgcaqwwr zjntujkfoo (svbtilskvq, +/ - 15.3)	-	01 Jan 2009
				Topical Anesthetic Gel	hrcrsqlvyp(jsaoohoooj) = rgkorresjs zjntujkfoo (svbtilskvq, +/ - 18.0)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis